MEDIVIS, Inc.

MEDIVIS develops FDA-cleared augmented reality (AR) and surgical navigation software for intraoperative guidance and preoperative planning. The company's flagship product, SurgicalAR, transforms 2D cross-sectional imaging (CT, MRI) into high-fidelity 3D visualizations with real-time surgical navigation and spatial computing capabilities. Primary offerings include: Spine Navigation (FDA-cleared for open and minimally invasive spine procedures), Cranial Navigation (FDA-cleared for EVDs, subdural evacuations, and craniotomies), and Prostate Navigation (research-stage for biopsies and ablations). SurgicalAR features on-premise IT infrastructure with certified gold-standard security, infrared instrument tracking by specialty, photorealistic 3D renderings, model segmentation, livestream imaging to virtual monitors, spatial hand and voice interactions, and an integrated AI agent (Maia, coming soon). Hardware platforms include Medivis PRO (27" touch monitor, 4K graphics, NVIDIA GPU for operating rooms), Medivis CORE (17" portable workstation for ICUs and clinics), and Medivis VIEWER (spatial computing visualization for planning). The company has deployed across 40+ hospitals and medical schools, with 2,000+ surgeries performed using SurgicalAR. Regulatory clearances include FDA 510(k) clearance for spine and cranial modules, CE marking, and Korea FDA clearance. The technology integrates with existing surgical workflows and imaging systems, supporting neurosurgery, orthopedic, and urological specialties. Recognized by TIME Magazine (Best Inventions 2023), Fast Company (Most Innovative 2024), and as Edison Award finalist (2024).